Overexpression of uridine diphospho glucuronosyltransferase 2B17 in high-risk chronic lymphocytic leukemia

Blood

Volumn 121, Issue 7, 2013, Pages 1175-1183

  Gruber, Michaela ^a   Bellemare, Judith ^b   Hoermann, Gregor ^a   Gleiss, Andreas ^a   Porpaczy, Edit ^a   Bilban, Martin ^a   Le, Trang ^a   Zehetmayer, Sonja ^a   Mannhalter, Christine ^a   Gaiger, Alexander ^a   Shehata, Medhat ^a   Fleiss, Karin ^a   Skrabs, Cathrin ^a   Lévesque, Éric ^b   Vanura, Katrina ^a   Guillemette, Chantal ^b   Jaeger, Ulrich ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Université Laval   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; CYCLOPHOSPHAMIDE; FLUDARABINE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A10; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 1A4; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 1A8; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B15; GLUCURONOSYLTRANSFERASE 2B17; GLUCURONOSYLTRANSFERASE 2B28; GLUCURONOSYLTRANSFERASE 2B7; GLYCOSYLTRANSFERASE; MESSENGER RNA; UNCLASSIFIED DRUG; VORINOSTAT;

ARTICLE; CANCER PROGNOSIS; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENOTYPE; GLUCURONIDATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT FREE SURVIVAL; UPREGULATION;

EID: 84874076739     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-08-447359     Document Type: Article

References (44)

1. Gribben JG. Molecular profiling in CLL. Hematol-ogy Am Soc Hematol Educ Program. 2008;2008: 444-449.
2. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46(2): 219-234.
3. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48(1):198-206. (Pubitemid 11064396)
4. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lym-phocytic leukemia. N Engl J Med. 2000;343(26): 1910-1916. (Pubitemid 32064784)
5. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6):1848-1854. (Pubitemid 29430400)
6. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94(6):1840-1847. (Pubitemid 29430399)
7. Oppezzo P, Vasconcelos Y, Settegrana C, et al. The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia. Blood. 2005;106(2):650-657. (Pubitemid 40981263)
8. Heintel D, Kienle D, Shehata M, et al. High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia. Leukemia. 2005; 19(7):1216-1223. (Pubitemid 40946007)
9. Bilban M, Heintel D, Scharl T, et al. Deregulated expression of fat and muscle genes in B-cell chronic lymphocytic leukemia with high lipopro-tein lipase expression. Leukemia. 2006;20(6): 1080-1088. (Pubitemid 43797301)
10. Beaulieu M, Levesque E, Hum DW, Belanger A. Isolation and characterization of a novel cDNA encoding a human UDP-glucuronosyltransferase active on C19 steroids. J Biol Chem. 1996; 271(37):22855-22862. (Pubitemid 26304735)
11. Beaulieu M, Levesque E, Tchernof A, Beatty BG, Belanger A, Hum DW. Chromosomal localization, structure, and regulation of the UGT2B17 gene, encoding a C19 steroid metabolizing enzyme. DNA Cell Biol. 1997;16(10):1143- 1154. (Pubitemid 27479382)
12. Chouinard S, Yueh MF, Tukey RH, et al. Inactiva-tion by UDP-glucuronosyltransferase enzymes: the end of androgen signaling. J Steroid Biochem Mol Biol. 2008;109(3-5):247-253.
13. Turgeon D, Carrier JS, Chouinard S, Belanger A. Glucuronidation activity of the UGT2B17 enzyme toward xenobiotics. Drug Metab Dispos. 2003; 31(5):670-676. (Pubitemid 36444177)
14. Balliet RM, Chen G, Gallagher CJ, Dellinger RW, Sun D, Lazarus P. Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype. Cancer Res. 2009;69(7):2981-2989.
15. Wong NS, Seah E, Wang LZ, et al. Impact of UDP-gluconoryltransferase 2B17 genotype on vorinos-tat metabolism and clinical outcomes in Asian women with breast cancer. Pharmacogenet Genomics. 2011;21(11):760-768.
16. McCarroll SA, Hadnott TN, Perry GH, et al. Common deletion polymorphisms in the human genome. Nat Genet. 2006;38(1):86-92. (Pubitemid 43011887)
17. Wilson W 3rd, Pardo-Manuel de Villena F, Lyn-Cook BD, et al. Characterization of a common deletion polymorphism of the UGT2B17 gene linked to UGT2B15. Genomics. 2004;84(4):707-714. (Pubitemid 39310948)
18. Xue Y, Sun D, Daly A, et al. Adaptive evolution of UGT2B17 copy-number variation. Am J Hum Genet. 2008;83:337-346.
19. Jakobsson J, Ekstrom L, Inotsume N, et al. Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism. J Clin Endocrinol Metab. 2006;91(2):687-693. (Pubitemid 43236944)
20. Spielman RS, Bastone LA, Burdick JT, Morley M, Ewens WJ, Cheung VG. Common genetic variants account for differences in gene expression among ethnic groups. Nat Genet. 2007;39(2): 226-231. (Pubitemid 46184354)
21. Gallagher CJ, Muscat JE, Hicks AN, et al. The UDP-glucuronosyltransferase 2B17 gene deletion polymorphism: sex-specific association with urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol glucuronidation phenotype and risk for lung cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(4):823-828. (Pubitemid 46650589)
22. Gallagher CJ, Kadlubar FF, Muscat JE, Ambrosone CB, Lang NP, Lazarus P. The UGT2B17 gene deletion polymorphism and risk of prostate cancer. A case-control study in Caucasians. Cancer Detect Prev. 2007;31(4):310-315. (Pubitemid 47562635)
23. Karypidis AH, Olsson M, Andersson SO, Rane A, Ekstrom L. Deletion polymorphism of the UGT2B17 gene is associated with increased risk for prostate cancer and correlated to gene expression in the prostate. Pharmacogenomics J. 2008;8(2): 147-151. (Pubitemid 351411551)
24. Olsson M, Lindstrom S, Haggkvist B, et al. The UGT2B17 gene deletion is not associated with prostate cancer risk. Prostate. 2008;68(5):571-575. (Pubitemid 351500217)
25. Nadeau G, Bellemare J, Audet-Walsh E, et al. Deletions of the androgen-metabolizing UGT2B genes have an effect on circulating steroid levels and biochemical recurrence after radical prostatectomy in localized prostate cancer. J Clin Endo-crinol Metab. 2011;96(9):E1550-1557.
26. Murata M, Warren EH, Riddell SR. Ahuman minor histocompatibility antigen resulting from differential expression due to a gene deletion. J Exp Med. 2003;197(10):1279-1289. (Pubitemid 36617774)
27. McCarroll SA, Bradner JE, Turpeinen H, et al. Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease. Nat Genet. 2009;41(12):1341-1344.
28. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008; 111(12):5446-5456.
29. Laverdiere I, Caron P, Harvey M, Levesque E, Guillemette C. In vitro investigation of human UDP-glucuronosyltransferase isoforms responsible for tacrolimus glucuronidation: predominant contribution of UGT1A4. Drug Metab Dispos. 2011;39(7):1127-1130.
30. Shehata M, Demirtas D, Schnabl S, et al. Sequential gene expression profiling during treatment for identification of predictive markers and novel therapeutic targets in chronic lymphocytic leukemia. Leukemia. 2010;24(12):2122-2127.
31. Abel U, Berger J, Wiebelt H. Critlevel: an exploratory procedure for the evaluation of quantitative prognostic factors. Method Inform Med. 1984; 23(3):154-156. (Pubitemid 14002516)
32. Vasconcelos Y, De Vos J, Vallat L, et al. Gene expression profiling of chronic lymphocytic leukemia can discriminate cases with stable disease and mutated Ig genes from those with progressive disease and unmutated Ig genes. Leukemia. 2005;19(11):2002-2005. (Pubitemid 41554014)
33. Haslinger C, Schweifer N, Stilgenbauer S, et al. Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status. J Clin Oncol. 2004;22(19):3937- 3949. (Pubitemid 41079876)
34. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B. 1995;57(1): 289-300.
35. Tian L, Greenberg SA, Kong SW, Altschuler J, Kohane IS, Park PJ. Discovering statistically significant pathways in expression profiling studies. Proc Natl Acad Sci USA. 2005;102(38):13544-13549. (Pubitemid 41420885)
36. Enjuanes A, Benavente Y, Bosch F, et al. Genetic variants in apoptosis and immunoregulation-related genes are associated with risk of chronic lymphocytic leukemia. Cancer Res. 2008;68(24): 10178-10186.
37. Kern W, Bacher U, Haferlach C, et al. Monoclonal B-cell lymphocytosis is closely related to chronic lymphocytic leukaemia and may be better classified as early-stage CLL [published online ahead of print January 9, 2012]. Br J Haematol. doi: 10.1111/j.1365.2141.2011.09010.x
38. Slager SL, Goldin LR, Strom SS, et al. Genetic susceptibility variants for chronic lymphocytic leukemia. Cancer Epidemiol Biomarkers Prev. 2010; 19(4):1098-1102.
39. Delmer A, Ajchenbaum-Cymbalista F, Tang R, et al. Overexpression of cyclin D2 in chronic B-cell malignancies. Blood. 1995;85(10):2870-2876.
40. Csanaky G, Matutes E, Vass JA, Morilla R, Catovsky D. Adhesion receptors on peripheral blood leukemic B cells. A comparative study on B cell chronic lymphocytic leukemia and related lymphoma/leukemias. Leukemia. 1997;11(3):408-415. (Pubitemid 27120991)
41. Aalto Y, El-Rifa W, Vilpo L, et al. Distinct gene expression profiling in chronic lymphocytic leukemia with 11q23 deletion. Leukemia. 2001;15(11): 1721-1728. (Pubitemid 33061839)
42. Li FJ, Ding S, Pan J, et al. FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia. Blood. 2008;112(1):179-187.
43. Perez-Perarnau A, Coll-Mulet L, Rubio-Patino C, et al. Analysis of apoptosis regulatory genes altered by histone deacetylase inhibitors in chronic lymphocytic leukemia cells. Epigenetics. 2011; 6(10):1228-1235.
44. Tamura K, Sawada H, Izumi Y, et al. Chronic lym-phocytic leukemia (CLL) is rare, but the proportion of T-CLL is high in Japan. Eur J Haematol. 2001;67(3):152-157. (Pubitemid 33105054)